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Abstract
Liquid biopsies contain numerous proteins coming from extracellular vesicles (EVs), be 
it microvesicles or exosomes, released by both normal and tumour cells, as well as the 
presence of any circulating tumour cells (CTCs). Such proteins can be used as biomark-
ers for early diagnosis, prognostic assessment, disease progression monitoring, therapy 
selection and treatment response, particularly in oncology. EVs have been identified 
as mediators of cell-to-cell communication in both normal and pathological conditions 
and suggested to play a role in promoting and maintaining cancer dissemination and 
progression by altering the tumour microenvironment through immune suppression, 
angiogenesis and metastasis. One class of proteins garnering particular interest are extra-
cellular heat shock proteins (HSPs) (secreted despite no consensus secretory sequence), 
and their post-translational modifications (PTMs), which are thought to act as key play-
ers in intercellular crosstalk and activation of signalling pathways during stress condi-
tions. This review will focus on how characterising and quantifying these proteins can 
indicate the condition of the physiological system in a variety of pathological contexts.
Keywords: extracellular vesicles, biomarkers, heat shock proteins (HSPs),  
post-translational modifications (PTMs), intercellular crosstalk
1. Introduction
Liquid biopsies may contain a wide variety of biomolecules including DNA, RNA, proteins 
and metabolites. When considering the presentation of the numerous proteins within a liquid 
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biopsy, these can be free in the plasma, encapsulated within or on the surface of extracellular 
vesicles (EVs) or still inside cells within the biopsy (such as in the case of circulating tumour 
cells (CTCs)).
One class of proteins garnering particular interest as part of liquid biopsies are extracellu-
lar heat shock proteins (HSPs), and their post-translational modifications (PTMs), mainly 
because they should not be present in body fluids at the concentrations observed due to their 
lack of an export sequence and also as a result of the growing evidence supporting the notion 
that these proteins can mediate intercellular crosstalk and act as messengers that activate 
signalling pathways during stress conditions.
1.1. Heat shock proteins (HSPs)
HSPs are a class of chaperone proteins ubiquitously expressed in the cells of both prokary-
otic and eukaryotic organisms. HSPs have been traditionally named and subdivided into six 
groups or families based on their molecular weight, namely, the small HSPs (which include 
HSP27), HSP40, HSP60, HSP70, HSP90 and HSP100 family. However, more recently, a new 
nomenclature and classification system based on the naming issued by the Human Genome 
Organisation (HUGO) Gene Nomenclature Committee (HGNC) has been proposed for clas-
sifying human HSPs into the following groups: HSPA (HSP70), HSPB (small HSPs including 
HSP27), HSPC (HSP90), HSPD/HSPE (HSP60/HSP10), HSPH (HSP110) and DnaJ (HSP40) 
[1]. Each of these families has members that are constitutively expressed and others that are 
inducible upon stress.
Under normal physiological conditions, constitutive HSPs fulfil important regulatory roles 
in a wide range of cellular processes including the synthesis, folding, translocation, assembly 
and in some cases activation of the proteins they interact with. On the other hand, after an 
episode of cellular stress, inducible HSPs help to refold and prevent aggregation of misfolded 
proteins, as well as assist in the proteasomal degradation of misfolded proteins which can-
not be recovered. Moreover, HSPs can block apoptotic signalling and increase tolerance to 
subsequent insults [2].
However, it is now starting to emerge that during stress, the role of HSPs goes beyond what 
is expected to be their intracellular chaperoning functions for recovery from multiple stress 
conditions. Despite HSPs acting predominantly intracellularly, they have also been found 
expressed in the cell plasma membrane and in the extracellular space. Numerous HSPs have 
been reported to be present in the extracellular space and general circulation, activating a 
range of signalling pathways depending on the effector cell type or target organ. The role of 
such extracellular HSPs appears to be that of a systemic warning system of stressful events or 
chronic conditions, acting by priming the body, of which the immune system is a major effec-
tor, in order to prepare for and counteract the spread of the stress insult. Extracellular HSPs 
thus seem to act as a form of intercellular communication system during stress conditions, 
particularly those responses linked to oxidative stress, immunity or inflammation [3].
1.2. The presence of HSPs outside cells
When HSPs are present outside cells, they can be found as free proteins in solution or forming 
part of EVs. EVs can be of various types, with distinct structural and biochemical properties 
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as well as intracellular site of origin. These include large microvesicles (up to 1500 nm) that 
are heterogeneous in shape and produced from the plasma membrane, small (50–100 nm) and 
more uniformly shaped exosomes released from endosomes via the endocytic pathway and 
apoptotic vesicles produced upon cell death [4, 5].
EVs are released by almost all cell types, both healthy and diseased (including tumour cells). 
Such vesicles carry a wide range of biologically active molecules including growth factors, 
cytokines, mRNAs and microRNAs, extracellular matrix constituents and also proteins [6]. 
The protein fraction consists of cytosolic or plasma membrane components, either inside or 
on the surface. Their molecular contents have been shown to mediate intercellular communi-
cation in a variety of cellular processes, in both normal and pathological conditions, with the 
transfer of such biomolecules altering the function of the target cells. In the context of cancer, 
for example, EVs can modulate both the tumour microenvironment and cells and tissues 
which are located at a distance, affecting the immunity in the area, promoting angiogenesis 
and bringing about metastasis [7, 8].
EVs are also released by cells in response to being exposed to a stressor or as a result of chronic 
cellular stress. Such EVs contain particular molecules, including HSPs, whose expression level 
is directly linked to or induced by the stress insult. Upon reaching their effector cells, and 
especially when interacting with cells of the immune system, some EV components act as 
signalling molecules, activating a response in the effector cells which pre-empts the stress 
insult prior to its spread [3].
Proteomic studies have shown that EVs from serum, saliva, milk or plural effusions contain 
HSP27, HSP60, HSP70 and HSP90 [9–16] at high concentrations, with the ability to synergise 
with other encapsulated factors [3]. The delivery of HSPs in EVs provides a much stronger 
signal to effector cells as exemplified by EVs containing HSP70 producing a 250-fold higher 
activation of macrophages than an equal concentration of HSP70 in solution [17].
The HSPs encapsulated within or presented on the surface of such EVs, together with chang-
ing levels in free HSPs, can thus be valuable disease biomarkers for early detection, diagnosis 
and therapy selection. However, in order to access them, these proteins need to be purified 
from the body fluids of patients, characterised, quantified and compared to what is known in 
the healthy condition.
2. Secretion and uptake of extracellular heat shock proteins
When cells are exposed to a stressor, which includes but is not limited to heat shock, osmotic 
stress, exposure to heavy metals, hypoxia, ischemia or pathogens, these release signalling 
molecules in order to alert the rest of the system that a stressful condition is being experienced 
in some part of the organism and which might potentially lead to a situation of systemic dam-
age. Among the stress signals which can be released by cells in response to an incidence of 
cellular stress are HSPs and other components of the chaperone (Figure 1). It is worth noting 
that most HSPs lack the consensus signal required for secretion via the classical endoplasmic 
reticulum (ER)-Golgi pathway [3, 18]. So far, it appears that the secretion of HSPs is achieved 
via a number of alternative pathways; however, these are still not well defined. Presently, the 
HSP release mechanisms identified are (but might not be limited to) processes via:
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i. Cell lysis—where the process can be the result of a physiologically regulated release of 
cytokines or necrosis resulting from a pathological condition. Extracellular HSP70 has 
been suggested to be released into circulation under a variety of pathological conditions 
which cause widespread cell death as well as the following necrosis of tumour cells [19].
ii. Endolysosomal pathway—where the HSP is translocated into lysosomes and instead of 
being degraded is translocated out of the cell via endocytosis. HSP27 (dephosphorylated 
at S15 and S82) [20] and HSP70 [21] have been shown to enter endolysosomes, which are 
then secreted extracellularly in an ATP-dependent manner, from both tumuor cells and 
macrophages possibly via some pathway analogous to the ATP-binding cassette (ABC) 
transport system [21].
iii. Exosomal pathway—where the HSP is contained in secretory vesicles (exosome lumen) 
which rupture or are lysed once present in the extracellular space. A number of HSPs 
have been detected within extracellular vesicles including HSP27, HSP70, HSC70, GRP75, 
GRP78 and HSP90 [22–25].
iv. Inclusion in the exosomal membrane—where the HSP is inserted into the membrane of 
the secretory vesicles rather than being in the lumen. The isolation of HSP70-containing 
vesicles, derived from the plasma membrane, indicates that the surface of the vesicle can 
be used as an export system [17, 26, 27].
v. Secretory-like granules—where the vesicles used to transport the HSP are neither lipid bod-
ies, nor endosomes, or lysosomes. Tumour cells were found to release HSP70 in structures 
that were only positive for chromogranin A, which is a marker of secretory granules [28].
Once in the extracellular space or general circulation, these HSPs can stimulate a wide range of 
cell types. However, similar to the secretion mechanisms, the recognition and uptake of HSPs 
by cells, as well as the role that extracellular HSPs play in cell activation, are poorly understood. 
HSPs have been reported to bind to a wide variety of receptors on target cells, among which are:
i. Low-density lipoprotein (LDL) receptor-related protein 1 (LRP1; CD91)—a receptor 
involved in receptor-mediated endocytosis, which is found on numerous cell types 
including antigen-presenting cells (APCs), known to bind to HSP70, HSP90 and calreti-
culin [29, 30].
ii. CD40—a member of the tumour necrosis factor (TNF) receptor family that is essential 
in mediating a broad variety of immune and inflammatory responses and can bind to 
HSP70 [31, 32].
iii. C-C chemokine receptor type 5 (CCR5; CD195)—a receptor on white blood cells involved 
in the process by which T cells are attracted to target areas via cytokines, which has also 
been shown to bind to mycobacterial HSP70 [33].
iv. Toll-like receptors (TLRs)—of the ten TLR receptors found in humans, only TLR2 and TLR4 
are so far known to act as HSP receptors. They are known to bind to HSP60, HSP70 and 
HSP90 [34–37]. It has been suggested that TLR activation by HSP is most likely not the result 
of a direct binding of HSP70 to these receptors but rather either a low affinity interaction or 
a secondary activation involving the prior binding of HSP to another receptor [38].
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v. CD14—a co-receptor for TLR4 activation, which was found to be also required for HSP70 
induction of cytokines [35].
vi. Scavenger receptors (SR)—a family of receptors currently classified into ten subclasses 
(A–J) based on structure and biological function [39]. At least three SRs bind to and 
internalise HSPs, namely, lectin-like oxidised LDL receptor 1 (LOX-1), scavenger recep-
tor expressed by endothelial cell 1 (SREC-1) and fasciclin and EGF-like, laminin-type 
EGF-like and link domain-containing scavenger receptor 1(FEEL-1)/common lymphatic 
endothelial and vascular endothelial receptor 1 (CLEVER-1), with HSP70 binding to all 
three, HSP60 binding to LOX-1, HSP90 binding to LOX-1 and SREC-1 and calreticulin 
binding SREC-1 but not LOX-1 [38, 40–43]. Furthermore, scavenger receptor-A (SR-A) can 
bind to and internalise HSP90 and calreticulin as well as HSP110 and GRP170 [42, 44]. The 
sialic acid-binding immunoglobulin-type lectin (Siglec) receptors Siglec-5 and Siglec-14 
have also been found to bind to HSP70 [45, 46].
Figure 1. Heat shock proteins (HSPs) are exported into the extracellular space and general circulation via a number of 
different processes including cell lysis, secretory vesicles, lysosomal endosomes or export vesicles. Once these extracellular 
HSPs reach the target tissues, they bind to a variety of receptors, which initiate an alarm response. When these extracellular 
HSPs are collected from patients with chronic diseases and quantified, they can have diagnostic or prognostic value.
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3. Biomarker potential of extracellular heat shock proteins
Changes in extracellular HSPs have been detected and implied to be actively involved in 
many chronic pathological conditions including arthritis, cardiovascular disease, cancer, type 
2 diabetes mellitus (T2DM), chronic obstructive pulmonary disease (COPD) and neurodegen-
erative diseases. However, in order for these extracellular proteins to be used as biomarkers 
for early diagnosis, prognostic assessment, disease progression monitoring, therapy selection 
or treatment response, it is essential to characterise their functions and quantify their levels in 
the selected body fluids for liquid biopsies under both normal physiological conditions and 
the various pathological contexts.
For example, with respect to cancer, a wide range of studies have linked changes in extracel-
lular HSPs to key mechanisms involved in either the process of malignant transformation or 
the progression of a tumour via evasion of apoptosis, increased cell proliferation and immor-
tality, invasiveness and metastasis. On the other hand, when it comes to T2DM, because the 
biochemical mechanisms are not well understood, it is more difficult to link extracellular 
HSPs to the aetiology of the condition. However, T2DM patients present a two- to fourfold 
higher risk of developing macrovascular diseases, including coronary artery disease, stroke 
and peripheral vascular disease, making episodes of cardiovascular complications the major 
fatality in such patients [47]. Moreover, the sustained hyperglycaemia brings about cellu-
lar dysfunction via systematic biochemical changes due to oxidative stress, accumulation of 
advanced glycated end products (AGEs) and chronic inflammation [48], which are processes 
highly associated with HSPs.
3.1. HSP27
Extracellular HSP27 has been so far linked to three major functions, immune response modu-
lation, angiogenesis and atheroprotection through a number of mechanisms, which in the 
contexts of cancer and T2DM can have a significant contribution to the aetiology or progres-
sion of the disease.
Immune signalling is activated by extracellular HSP27 via interaction with receptors on the 
surface of immune or endothelial cells, leading to the differential production and release of 
cytokines and growth factors, in order to modulate the immune response, cellular migration 
and proliferation. Extracellular HSP27 interacts with TLR2, TLR3 and TLR4, bringing about 
NF-κB transcriptional activation and the upregulation of intercellular adhesion molecule-1 
(ICAM-1) and monocyte chemoattractant protein-1 (MCP-1), leading to the secretion of TNF-α, 
IL-6, IL-8, IL-10, IL-1β, IL-12p35 and IL-12p40, colony-stimulating factor 2 (CSF2) and vascular 
endothelial growth factor (VEGF) [49–52]. The release of IL-10 induced by extracellular HSP27 
was found to involve the phosphorylation of p38 and MAPKAPK-2, whilst the upregulation of 
TNF-α was attributed to the activation of both p38 and ERK1/ERK2 signalling pathways [53]. 
HSP27 was also found to interact with oestrogen receptor-β (ER-β) [54, 55].
In cancer, extracellular Hsp27 has been reported to exert pro-angiogenic effects via the stimula-
tion of the transcription of the vascular endothelial growth factor (VEGF) gene [50]. Increased 
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VEGF expression promoted HSP27 phosphorylation through the stress-activated protein 
kinase 2 (SAPK-2)/p38 pathway, resulting in cytoskeletal rearrangements and endothelial cell 
migration [56]. Furthermore, HSP27 phosphorylation not only reduced the release of HSP27 in 
the extracellular space, where the released HSP27 binds to and blocks VEGF [20], but also 
enhanced intracellular VEGF expression by interacting with the TLR3 on endothelial cells [50].
In the context of diabetes, T2DM patients with cardiovascular disease presented no significant 
change in serum HSP27 than non-diabetic controls [57]. However, extracellular HSP27 levels 
were found to be inversely correlated to progression, complexity and instability of plaques 
found in atherosclerotic human coronary arteries [54, 58], with HSP27 secretion being greatly 
reduced in atherosclerotic lesions and almost absent in complicated plaques [59]. Lower lev-
els of serum HSP27 were described as being predictive of subsequent heart attacks, strokes 
or cardiovascular death within the following 5 years [60]. Atheroprotection is thought to be 
mediated through oestrogen (for the extracellular release of HSP27) as well as via modulation 
of various processes involved in atherosclerosis, such as cholesterol homeostasis and traffick-
ing, regional inflammation (including mobility of immune cells in plaques and macrophage 
activation into foam cells) and plaque remodelling by extracellular HSP27 [61]. Extracellular 
HSP27 seems to be involved in reduced lipid engulfment by macrophages and foam cell 
formation through the blocking and downregulation of macrophage scavenger receptor A 
[62, 63], as well as the promotion of cholesterol efflux by enhancing ATP-binding cassette 
(ABC) transporter activity via the TLR4-induced and NF-κB-mediated release of CSF2 [64]. A 
similar activation of NF-κB in endothelial cells via TLR2, TLR3 and TLR4 may further worsen 
the condition [50, 51]. Moreover, patients with T2DM presented accelerated platelet aggrega-
tion correlated with the release of phosphorylated HSP27 from platelets induced by thrombin 
receptor-activating protein (TRAP) activation of Akt and p38 MAP kinase [65, 66].
3.2. HSP60
Till now, extracellular HSP60 has not been linked to any specific function. What has been 
explored so far is mostly related to its release mechanism. It has been shown that HSP60 
is released into the extracellular space via the exosomal pathway, with most of the HSP60 
tightly bound to (as opposed to embedded in) the exosomal membrane, rather than housed in 
the lumen of the exosomes. Moreover, evidence indicates that exosomal HSP60 is at least in 
part ubiquitinated (but not poly-ubiquitinated, i.e. not marked for degradation), which might 
act as a signal for the sorting of HSP60 to exosomes [12]. This ties in with its presence in cancer 
and T2DM, although the significance of its role in the aetiology or disease progression have 
not been well investigated.
When looking at the cancer context, tumours often tend to present HSP60 in the cell mem-
brane [67] as well as secreted via exosomes [68]. It is hypothesised that cellular stress results in 
ubiquitination and possibly other post-translational modifications on cytosolic HSP60, which 
lead to its localisation in the cell membrane and consequently internalisation via lipid rafts, 
accumulation in multivesicular bodies and release into the extracellular space via the exosomal 
pathway [12]. Once secreted (either alone or in conjunction with other biomolecules), it then 
fulfils an as-yet unspecified but probably immunomodulatory extracellular function [69, 70]. 
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Bioinformatic analysis of colorectal cancer (CRC) pointed at the HSP60 gene as one of the best 
indicators for diagnosis [71] and proteomic studies have corroborated this finding [72] giv-
ing it diagnostic and prognostic value. Similarly, HSP60 has also been found to be linked to 
Crohn’s disease and ulcerative colitis [73], two conditions with a high risk for CRC develop-
ment, probably having a pro-inflammatory role in the remodelling of the colonic mucosa via 
a TLR4-ERK-dependent mechanism [74].
Extracellular HSP60 is also thought to play a role in diabetes, as stresses associated with diabe-
tes result in the expression of HSP60 on the cell surface as well as its extracellular release, such 
that it has been detected in both the serum and the saliva of T2DM patients [75, 76]. Moreover, 
T2DM patients with cardiovascular disease were associated with higher levels of circulating 
HSP60 compared to control subjects without cardiovascular disease [77]. Extracellular HSP60 
has been associated with the severity of atherosclerosis and has been proposed as a biomarker 
for coronary heart disease [78, 79].
3.3. HSP70
Extracellular HSP70 has been shown to have important immunostimulatory properties, acti-
vating macrophages, monocytes, dendritic cells (DCs) and natural killer (NK) cells, by acting 
either as a cross presenter of immunogenic peptides via major histocompatibility complex 
(MHC) antigens, as a chaperone stimulating both innate and adaptive immunities, or as 
a stimulator and target for innate immune responses mediated by NK cells [35, 80, 81]. In 
contrast, some studies have shown that it can also have anti-inflammatory effects by activat-
ing both immunosuppressive regulatory T cells (Tregs) and Siglec receptors that block the 
inflammatory process by interacting with TLRs [82]. Moreover, extracellular HSP70 bound to 
vesicle membranes has been shown to induce an immunosuppressive effect [27], supporting 
the notion that HSP70 fulfils different roles depending on the composition, source and effec-
tor of the vesicles it is associated with.
Apart from immunity, extracellular HSP70 has been implicated in a wide array of conditions 
including cancer, diabetes, chronic inflammation, cardiovascular disease, hypertension, pre-
eclampsia, Alzheimer’s disease (inhibiting amyloid β aggregation) and ischemia [3, 83, 84].
When it comes to the cancer setting, serum HSP70 levels have been correlated with treat-
ment response and tumour volume [85], making extracellular HSP70 a potential biomarker 
for cancer [86] both as a candidate biomarker for tumour detection and monitoring clinical 
outcome of radiotherapy [87], as well as a prognostic marker, such as in CRC, associated with 
rapid disease progression and poor survival [88]. In some contexts, extracellular HSP70 has 
even shown potential in discriminating between infection or inflammation and cancer (e.g. 
chronic hepatitis, liver cirrhosis and hepatocellular carcinoma) [89]. Extracellular HSP70 has 
been found to increase MMP9 expression by activating NF-κB and AP-1 and that the subse-
quent increase in pro-MMP9 secretion results in enhanced cell motility and invasiveness [90]. 
HSP70 was also isolated from the surface of tumour-derived exosomes [26], in which setting 
it can interact with myeloid-derived suppressor cells, so as to suppress T-cell activation and 
promote cancer development [27]. Extracellular HSP70 has also been used as a cancer vaccine, 
such that immunisation of mice with a vaccine made of HSP70-peptide complexes extracted 
Liquid Biopsy108
from fusions between DCs and radiation-enriched tumour cells resulted in a T-cell-mediated 
immune response against radioresistant tumour cells [91].
In vitro experiments of diabetes have shown that extracellular HSP70 plays a role in diabetic 
nephropathy in T2DM by promoting inflammation in the proximal tubule cells via a TLR4-
NF-κB pathway. HSP70 release induced by the albumin in the proximal tubule cells triggered the 
overexpression of the inflammatory cytokines monocyte chemoattractant protein’ 1 (MCP-1), 
tumour necrosis factor alpha (TNF-α) and macrophage inflammatory protein 2 (MIP2) [92]. 
Similar results were obtained in diabetic mice where TLR4 deletion or HSP70 inhibition reduced 
albuminuria and markers of inflammation and tubular injury [92]. Further supporting these 
findings, patients with T2DM with albuminuria showed higher serum HSP70 levels [93] as 
well as an association between urinary HSP70 levels and albuminuria [94]. Serum HSP70 was 
also found to be higher in patients with diabetic retinopathy, together with HIF-1α compared 
with subjects without [95] and correlated well with asymmetric dimethylarginine (ADMA) 
and C-reactive protein (CRP) levels in T2DM patients compared with healthy controls [96].
An inverse association has been reported between levels of HSP70 with the presence and 
severity of cardiovascular disease [97–100]. Moreover, an inverse correlation was found 
between HSP70 levels and the risk of future development of atherosclerosis in subjects with 
established hypertension [101]. Extracellular Hsp70 levels have also been inversely corre-
lated with the risk of cardiovascular disease [97, 101, 102] and the severity and survival after 
chronic heart failure [103].
3.4. GRP78
Extracellular GRP78 has been documented [104, 105], but it has been studied much more 
extensively at the cell surface than in the extracellular space or in circulation. GRP78 could 
be detected in plasma as both full-length and C-terminus fragments [106]. GRP78 is secreted 
from cells via exosomes, and the release appears to be at least partly controlled by acetylation 
since the use of histone deacetylase (HDAC) inhibitors could block GRP78 release, causing 
aggregation in the ER. Suppression of HDAC6 activity leads to GRP78 acetylation, which 
is then bound to vacuolar protein sorting 34 (VPS34), a class III phosphoinositide-3 kinase, 
preventing GRP78 from being sorted into multivesicular bodies [107]. Since it has been shown 
that ER stress can actively promote the expression of GRP78 on the cell surface, and that 
over-expression of GRP78 can result in similar cell surface localisation, independent of ER 
stress [102], this might also hold true for extracellular release of GRP78. Once in the plasma 
membrane GRP78 binds to a wide selection of proteins, which in turn causes signalling cas-
cades through multiple pathways that can result both in cell survival and cell death [108, 109], 
however the potential interaction or competition of extracellular GRP78 has not been explored. 
Interestingly, HSP40 (DnaJ) seems to be involved in GRP78 cell surface localisation and silenc-
ing of the murine homolog, MTJ-1 abolished cell surface localisation of GRP78 [110], but so far 
its possible involvement in extracellular release instead has not been investigated.
When looking at cancers, extracellular GRP78 is not commonly investigated; however, some 
tumours secrete significant levels of GRP78 into the tumour microenvironment [105], and in 
one study, extracellular GRP78 was identified exclusively in the sera of 28% of gastric cancer 
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patients but not in healthy controls [111]. It is speculated that ER stress and activation of the 
unfolded protein response (UPR), an evolutionarily conserved mechanism in which survival 
or apoptotic pathways are activated in response to ER stress, induce GRP78 in tumour cells 
leading to increased secretion of GRP78, and by binding to cell surface receptors of endothe-
lial cells, extracellular GRP78 activates ERK and AKT pathways [105].
Useful inferences could be made by looking at cell surface GRP78 which is expressed signifi-
cantly in human tumours and generally associated with cell proliferation, cell survival, angio-
genesis and metastasis [112]. Cell surface GRP78 interacts with α2-macroglobulin, a plasma 
protease inhibitor, through its amino-terminal domain-activating the PI3K/Akt, ERK1/ERK2 
and p38 MAPK pathways, promoting cell proliferation and cell survival via Akt and NF-kB 
signalling cascades, by inducing the UPR [105, 113, 114]. Moreover, interaction of cell sur-
face GRP78 with teratocarcinoma-derived growth factor 1 (TDGF1; Cripto-1), a small, glyco-
sylphosphatidylinositol (GPI)-anchored protein, modulates activin-A, activin-B, nodal and 
transforming growth factor-b (TGF-b)-dependent signalling of several ligands via the MAPK/
PI3K and Smad2/3 pathway and promotes cell proliferation, downregulates E-cadherin 
(which decreased cell adhesion) and promotes pro-proliferative responses to activin-A and 
nodal [115, 116]. Of particular interest is that specifically on the surface of cancer cells but 
not healthy cells, GRP78 interacts via its amino-terminal domain with extracellular prostate 
apoptosis response 4 (Par-4), which together with tumour necrosis factor-related apoptosis-
inducing ligand or Apo 2 ligand (TRAIL/Apo2L) mediates apoptosis via an extrinsic apoptotic 
pathway (dependent on ER stress and the Fas-associated death domain (FADD)/caspase-8/
caspase-3 pathway) [117]. Similarly, plasminogen kringle 5 (K5), an angiogenesis inhibitor, 
interacts with cell surface GRP78 via the carboxy-terminal domain, on hypoxic and cytotoxic 
stressed tumour cells, mediating anti-angiogenic and pro-apoptotic activity following the 
internalisation of GRP78 by the scavenger receptor low-density lipoprotein receptor-related 
protein 1 (LRP1) and activation of p38 mitogen-activated protein kinase [118, 119].
The isolation of a tumour-specific variant of GRP78 containing an O-linked carbohydrate moi-
ety with a molecular weight of 82 kDa opens up numerous therapeutic possibilities not only 
of targeting tumours by specific variants of GRP78 [120] but also of searching for the presence 
of tumour-specific variants in circulation, as a diagnostic marker.
Once again in the context of diabetes, extracellular GRP78 is poorly investigated. However, 
data from cell surface expression of GRP78 indicates that the extracellular counterpart might 
play some role in the cardiovascular complications linked to T2DM. GRP78 has been detected 
on microparticles shed from activated endothelial cells indicating that GRP78 expression may 
be involved in regulating thrombosis [121]. Expression of cell surface GRP78 in arterial ath-
erosclerotic lesions negatively regulates the initiation of the tissue factor(TF)-mediated coagu-
lation cascade [122, 123], attenuating procoagulant activity similar to the effect observed from 
the binding of K5 to cell surface GRP78 on stimulated endothelial cells [119]. Atherosclerotic 
lesions also present an increase in truncated cadherin (T-cadherin) expression, which inter-
acts with cell surface GRP78, similar to the interaction on vascular endothelial cells [124] and 
on endothelial cells during tumour angiogenesis [125], promoting cell survival and indicating 
that this interaction plays a role in vascular tissue remodelling related to stress.
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3.5. HSP90
As with most other HSPs, extracellular HSP90 has been mainly studied in relation to inflam-
mation and immunity [126]. However, no specific roles, processes or mechanisms have been 
elucidated yet.
In the context of cancer, extracellular HSP90 (mainly not only HSP90a but also HSP90b) is 
known to be involved in tumour cell migration, invasion and metastasis [127–131]. Serum 
levels of extracellular Hsp90a were significantly higher in the patient groups with tumour 
burden, with a positive correlation with tumour malignancy and metastasis [132]. The interac-
tion of extracellular Hsp90 with the LRP1 receptor as well as HER-2 activates AKT1/AKT2 (in 
the phosphatidylinositol-3-kinase (PI3K) signalling pathway) and ERK1/ERK2 signalling cas-
cades giving rise to increased cell migration, supporting growth and survival [128, 133, 134]. 
AKT activation is sustained by the phosphorylation of the receptor tyrosine kinase ephrin 
type-A receptor 2 (EPHA2), which is a downstream product of the interaction between LRP1 
and extracellular Hsp90 [135]. Also, critical for cell migration is the presence of extracellular 
HSP90 for the interaction between Src and integrin β1 at focal adhesion points between the cell 
and ECM [130]. The interaction of extracellular HSP90 with TLR4 also signals through Src, and 
this transactivates the epithelial growth factor receptor (EGFR), which increases cell migration 
[136]. It has also been shown that extracellular HSP90 can have a role in ECM remodelling or 
stabilisation via its direct interaction with fibronectin [137]. Work in colorectal cancer cells 
showed that extracellular Hsp90 promotes epithelial-to-mesenchymal transition (EMT) via 
an LRP1-NF-κB pathway [138], whilst exposure of prostate cancer cells to extracellular Hsp90 
promoted EMT via a process requiring both matrix metalloprotein 9 (MMP9) and ERK activ-
ity [139]. Extracellular Hsp90 was also shown to interact with MMP2 [140]. The activation 
of ERK by extracellular Hsp90 has also been shown to increase expression of the polycomb 
repressor complex methyltransferase enhancer of zeste homologue 2 (EZH2), bringing about 
the epigenetic repression of E-cadherin [141], further supporting the EMT process.
Extracellular HSP90 has not been studied much in the context of diabetes, with the majority 
of studies investigating HSP90 inhibition in general and thus focusing on intracellular mecha-
nisms whilst not excluding effects by extracellular HSP90. In response to oxidative stress, 
vascular smooth muscle cells secrete HSP90a, and the stimulation of these cells by HSP90a 
induces MAPK activity [142]. Similarly, endothelial cells also secrete HSP90 upon activation, 
and this stimulates angiogenesis [143]. Experiments in diabetic rats have shown that annexin 
II on endothelial cells interacts with extracellular HSP90a, modulating plasminogen activa-
tion to plasmin [144]. Furthermore, HSP90 levels were found to be higher in the serum of 
patients with atherosclerosis [145]. Exosomes collected from cultured fibrocytes contained 
HSP90a (among other biomolecules) and enhanced cellular migration and proliferation as 
well as secretion of type I collagen (COL1) and type III collagen (COL3) and expression of 
α-smooth muscle actin (α-SMA) [146]. Inhibition of total HSP90 disrupts the IKK complex 
[147] and JAK2 protein stability [148], blocking the activity of the transcription factors NF-kB 
[149] and STAT [150], respectively, together with a downregulation in the expression of pro-
atherogenic cytokines and chemokines. Dysregulated NF-kB and STAT pathways contribute 
to diabetic nephropathy [150, 151] and atherosclerosis [152, 153]. The inhibition of HSP90 thus 
The Diagnostic and Prognostic Application of Heat Shock Proteins and their Post-Translational…
http://dx.doi.org/10.5772/intechopen.79737
111
modulates inflammation and oxidative stress, improving diabetes-associated renal damage 
and atheroprogression [154], insulin sensitivity [155], high-fat-diet-induced renal failure [156] 
and diabetic peripheral neuropathy [157].
4. Conclusion
The need to identify biomarkers for complex systemic and chronic diseases is pressing, with 
an increasing push towards the successful development of therapies aimed at modulating 
serum levels, blocking receptor binding or inhibiting signalling cascades. HSPs hold great 
potential as therapeutic targets for those conditions with underlying mechanisms involv-
ing accumulation of misfolded or damaged proteins, oxidative stress, altered mitochondrial 
bioenergetics or dysregulated apoptosis, particularly as a result of their non-chaperoning 
functions. Studies presented herein suggest that circulating HSP levels may be exploited as 
biomarkers of such conditions, with cancer and cardiovascular complications linked to T2DM 
being the contexts used to exemplify.
A major limitation of most studies performed on extracellular HSPs is that their functions 
and roles in disease have not been elucidated yet. As a result the biochemistry and signalling 
are investigated very poorly, such as testing for a single downstream product of a complex 
cascade which can be affected by multiple inputs. Similarly, the PTMs on extracellular HSPs 
are still in their majority obscure both in abundance and functional significance. Studies con-
ducted retrospectively, on single HSPs in isolation, using small patient groups and without 
adjustment for confounding effects offer a very poor analysis of the predictive power of HSPs 
for early diagnosis or prognostic assessment. Thus, in future research, it is important to take 
into consideration that HSPs do not work in isolation, but act within a network, rather than 
just detect changes in the total extracellular expression levels of individual HSPs and analyse 
changes in both total HSP and specific PTMs within groups of chaperone proteins that are 
functionally relevant to either the development of or resultant from the progression of the 
condition under investigation. Furthermore, this needs to be performed in large cohorts of 
well-characterised patients, with prospective validation of promising biomarker panels, if the 
intent is really their application in a clinical setting.
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